

1 **Transmission dynamics and epidemiological characteristics of Delta variant infections**
2 **in China**

3

4 Min Kang^{1*}, Hualei Xin^{2*}, Jun Yuan³, Sheikh Taslim Ali^{2,4}, Zimian Liang⁵, Jiayi Zhang¹,
5 Ting Hu¹, Eric H. Y. Lau^{2,4}, Yingtao Zhang¹, Meng Zhang¹, Benjamin J. Cowling^{2,4}, Yan Li^{1‡},
6 Peng Wu^{2,4‡}

7

8 * These authors contributed equally (joint first authors).

9 ‡ These authors contributed equally (joint senior authors).

10

11 **Affiliations:**

12 1. Guangdong Provincial Center for Disease Control and Prevention, Guangdong province,
13 China

14 2. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
15 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
16 Special Administrative Region, China.

17 3. Guangzhou Center for Disease Control and Prevention, Guangdong province, China

18 4. Laboratory of Data Discovery for Health Limited, Hong Kong Science Park, New
19 Territories, Hong Kong.

20 5. Foshan Center for Disease Control and Prevention, Guangdong province, China

21

22 **Corresponding authors:**

23 Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The

24 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong

25 Tel: +852 3917 6711; Email: bcowling@hku.hk

26 and

27 Yan Li, Guangdong Provincial Center for Disease Control and Prevention, Guangdong

28 province, China;

29 Tel: +86 2031051493; Email: sjkzx_liyan@gd.gov.cn

30

31 Running head: Epidemiology of Delta variant in China

32

33 Word count (abstract): 248

34 Word count (main text): 3,338

35

36

37 **ABSTRACT**

38 **Background:** The Delta variant of SARS-CoV-2 has become predominant globally. We
39 evaluated the transmission dynamics and epidemiological characteristics of the Delta variant
40 in an outbreak in southern China.

41 **Methods:** Data on confirmed cases and their close contacts were retrospectively collected
42 from the outbreak that occurred in Guangdong, China in May-June 2021. Key
43 epidemiological parameters, temporal trend of viral loads and secondary attack rates were
44 estimated and compared between the Delta variant and the wild-type SARS-CoV-2 virus. We
45 also evaluated the association of vaccination with viral load and transmission.

46 **Results:** We identified 167 patients infected with the Delta variant in the Guangdong
47 outbreak. The mean estimates of the latent period and the incubation period were 4.0 days
48 and 5.8 days, respectively. A relatively higher viral load was observed in Delta cases than in
49 wild-type infections. The secondary attack rate among close contacts of Delta cases was 1.4%,
50 and 73.9% (95% confidence interval: 67.2%, 81.3%) of the transmissions occurred before
51 onset. Index cases without vaccination (OR: 2.84, 95% confidence interval: 1.19, 8.45) or
52 with one dose of vaccination (OR: 6.02, 95% confidence interval: 2.45, 18.16) were more
53 likely to transmit infection to their contacts than those who had received 2 doses of
54 vaccination.

55 **Discussion:** Patients infected with the Delta variant had more rapid symptom onset. The
56 shorter and time-varying serial interval should be accounted in estimation of reproductive
57 numbers. The higher viral load and higher risk of pre-symptomatic transmission indicated the
58 challenges in control of infections with the Delta variant.

59

60 INTRODUCTION

61 The SARS-CoV-2 Pango lineage B.1.617.2, also known as the Delta variant, is a variant of
62 SARS-CoV-2 first detected in India on 7 September 2020 (1). It was classified by the World
63 Health Organization as a “Variant of Concern” on 11 May 2021, and has been rapidly
64 outcompeting other variants of SARS-CoV-2 and becoming predominant in many locations
65 around the world. As of 3 August 2021, a total of 135 countries have reported cases of the
66 Delta variant, and over 80% of new infections globally were expected to be due to Delta
67 since mid-June (1, 2).

68

69 Compared to the wild-type virus, the Delta variant has 9-10 characteristic mutations
70 including T19R, G142D, 156del, 157del, R158G, L452R, T478K, D614G, P681R, and
71 D950N which could be responsible for competitive advantages against other variants (3).
72 Residue 452 spike mutation located at the receptor binding domain may increase capability of
73 immune evasion and resistance to antibody neutralization, and P681R in the S1/S2 regions of
74 S gene could influence proteolytic processing (4). All these mutations could result in
75 increased affinity of ACE2 and resistance to antibody neutralization therefore leading to
76 increases in transmissibility (4). The basic reproduction number (R_0) of Delta variant was
77 suggested to be 55%-97% higher than other variants (2).

78

79 On 21 May 2021 the first local Delta case in mainland China was identified in Guangdong
80 province. A local outbreak occurred in the following days and weeks, and the gene sequence
81 analysis showed that all cases identified in this outbreak were infected with the Delta variant
82 and could be traced back to the index case (5). Aggressive case finding strategy including
83 multiple comprehensive large-scale nucleic acid tests in high-risk communities, routine PCR
84 testing for close contacts quarantined in designated places and nucleic acid screening among

85 inpatients and outpatients in clinical institutions, had been strictly implemented aiming to
86 identify all infected persons and rapidly control this outbreak. This provides uniquely rich
87 epidemiological data on infections with the Delta variant. In this study, we aimed to explore
88 the transmission dynamics and epidemiological characteristics of the Delta variant outbreak
89 in China. As the coverage of COVID-19 vaccination has increased substantially in China
90 since March 2021, we were able to examine the associations between vaccination and virus
91 shedding and transmission.

92

93 **METHODS**

94 *Data collection*

95 We retrospectively collected information on all laboratory-confirmed symptomatic and
96 asymptomatic cases with Delta (B.1.617.2) variant infection from the outbreak in Guangdong
97 province in May and June 2021. To estimate the latent period distribution, we collected
98 individual information on the first and last dates of exposure (exposure window), and the
99 repeated laboratory testing dates of last negative PCR test (lower bound of viral shedding)
100 and first positive PCR test (upper bound of viral shedding) which provide a window during
101 which detectable virus shedding began. We also obtained illness onset dates for incubation
102 period estimation. We reconstructed the transmission pairs from available illness onset dates
103 for both infectors and infectees to estimate the serial interval distribution, the infectiousness
104 profile, and the proportion of transmission occurring prior to symptom onset. Severity status
105 including asymptomatic, mild, moderate, severe and critical were collected for each case,
106 along with other information such as sex, age, pre-existing underlying conditions, vaccination
107 status, and exposure duration. We also collected information on close contacts of the
108 confirmed Delta cases to estimate secondary attack rates and identify predictors of infection.
109

110 Comprehensive large-scale nucleic acid-testing strategies, including community-wide PCR
111 testing, routine test among concentrated quarantine close contacts and daily test for inpatients,
112 were implemented in every local COVID-19 outbreak in China since April 2020 (6). For each
113 case, serial samples were collected and tested for both N-gene and OR-gene from the date of
114 first positive PCR test until discharge from hospital. To understand the temporal dynamics of
115 viral RNA shedding for the Delta variant, we obtained serial cycle threshold (C_t) values for
116 each case for N-gene with throat swabs from the first time of positive test (C_t value <40). To
117 make a comparison of viral loads between the Delta variant and the wild-type variant, we
118 used data of wild-type SARS-CoV-2 infections that were identified in Guangzhou, China in
119 early 2020 from a published paper on individual cases with daily test results (7).

120

121 *Case definitions*

122 A patient is confirmed as a COVID-19 case based on a positive result of PCR for SARS-
123 CoV-2 with respiratory specimens. Virus strains in this study were determined by the
124 sequenced genome and were classified based on the “Pango lineages” rule (8). The time
125 interval between infection and becoming infectious is defined as the latent period, that could
126 be compared with the incubation period which describes the time duration between infection
127 and symptom onset. The latent period is typically proxied by the time from infection until an
128 infected person has virus shedding that is detectable by PCR, and can be shorter than the
129 incubation period for some COVID-19 cases when virus shedding becomes detectable prior
130 to symptom onset. The serial interval, defined as the time interval between successive
131 symptom onsets in a transmission chain, is an important parameter for estimating many other
132 key epidemiological parameters, such as R_0 , the expected number of secondary cases
133 generated from one primary case in a completely susceptible population, and the
134 instantaneous reproduction number (R_t) which describes the expected number of secondary

135 cases caused by one typical primary case at time t . The infectiousness profile of COVID-19
136 describes the duration and intensity of infectiousness of infected cases which imply the
137 probability of transmission during the infectious period.

138

139 We assessed the clinical severity of COVID-19 cases via clinical classification into
140 asymptomatic, mild, moderate, severe and critical following the Guidelines in Diagnosis and
141 Treatment of COVID-19 (8th version) published by National Health Commission since 15
142 April 2021 (9).

143

144 Close contacts were defined as individuals who were exposed to symptomatic COVID-19
145 cases within two days before their illness onset, or exposed to asymptomatic cases at close
146 proximity (<1 meter) without wearing proper personal protection equipment within two days
147 before their sampling dates of the first positive samples for SARS-CoV-2. Close contacts
148 were classified as household and extended family, social, community and healthcare contacts
149 based on the definitions previous published by *Sun et al* (10). Cases were considered having
150 effective 1-dose vaccination if the start date of exposure was 10 days after the first dose of
151 vaccination or later, or having effective 2-dose vaccination if the start date of exposure was
152 14 days after the second dose of vaccination or later (11, 12).

153

154 ***Statistical analysis***

155 We used a maximum likelihood-based inferential method to estimate the distributions of
156 latent period, incubation period and serial interval and the infectiousness profile of confirmed
157 COVID-19 cases by fitting Gamma distributions. We accounted for the interval censoring of
158 exposure and viral shedding windows when estimating the latent period and incubation
159 period distributions. To estimate the infectiousness profile for symptomatic cases, we used a

160 method previously published by *He et al.* (7) which considered the serial interval as a
161 convolution between the infectiousness profile and the incubation period and allowed for an
162 early occurrence of infectiousness before symptom onset.

163

164 The time-varying forward serial intervals (13, 14) and daily numbers of cases were used to
165 estimate the daily R_t by applying the statistical methods developed by *Cori et al* (15). The
166 serial interval distribution and R_0 were obtained by using mean estimates of the serial interval
167 and R_t during the exponential growth phase of the Delta outbreak (14).

168

169 The overall temporal trend of Ct values for N-gene for Delta cases was analyzed by day of
170 illness onset. To aid visualization, smoothing splines using generalized additive models
171 (GAMs) (including days of illness onset as the only predictor) were fitted to the Ct values to
172 characterize the overall trend for the Delta variant. To make a comparison between Delta and
173 wild-type, we also fitted the temporal trend of Ct values for the Delta variant and wild-type
174 separately by excluding severe and critical and vaccinated Delta cases, because no severe or
175 critical or vaccinated cases were identified in wild-type cases. To evaluate the impact of
176 vaccination on viral loads among Delta cases, we fitted a multivariate GAMs by including
177 variables of vaccination (1: without vaccination, 2: with one or two dose of vaccine), days of
178 illness onset, age and disease severity. Temporal trend of predicted Ct values from the GAMs
179 model was presented and compared using box plots for vaccinated and unvaccinated cases
180 separately.

181

182 Close contacts of confirmed COVID-19 cases infected with Delta variant with a solely
183 possible source of infection for each close contact were included for analyzing. The overall
184 secondary attack rate was calculated by dividing the number of infections by the total number

185 of close contacts. To assess the effectiveness of vaccination against transmission, a stepwise
186 logistic regression model was fitted by including age, sex, disease severity of the index,
187 COVID-19 vaccination for index cases, COVID-19 vaccination for close contacts, type of
188 contact, presence of exposure on the symptom onsets of index cases and duration of exposure.
189 Non-parametric and parametric bootstrap approach with 1000 resamples was used to assess
190 the uncertainty of each estimated parameter. Analyses were carried out using R version 4.0.3
191 (R Foundation for Statistical Computing, Vienna, Austria).

192

193 **RESULTS**

194 As of 18 June 2021, 167 Delta cases were identified in the outbreak in Guangdong. Sixty-
195 nine (41.3%) were male. The median age was 47.0 years (interquartile range [IQR]: 31.0,
196 66.5) with 22 (13.2%) cases aged under 15 years and 44 (26.3%) over 65 years. The number
197 of asymptomatic, mild, normal and severe or critical was 8 (4.8%), 29 (17.4%), 111 (66.5%)
198 and 19 (11.4%), respectively, with no reported deaths. Sixteen (9.6%) cases received 2 doses
199 of the inactivated COVID-19 vaccine and 30 cases (18.0%) received one vaccine dose.

200

201 We examined data from 101 confirmed Delta cases with sufficient information to estimate
202 the time window for infection and the time window for the start of viral shedding. The mean
203 latent period was estimated to be 4.0 days (95% confidence interval [CI]: 3.5, 4.4). Ninety-
204 five percent of the Delta cases started shedding virus within 8.2 days (95% CI: 7.1, 9.3) after
205 infection (Figure 1A). The mean incubation period estimated from 95 symptomatic Delta
206 cases was 5.8 days (95% CI: 5.2, 6.4). The 95th percentile of the incubation period for Delta
207 was 11.5 days (95% CI: 10.1, 13.0) (Figure 1B).

208

209 We used data from 94 transmission pairs of Delta cases with a reported onset date to estimate
210 the infectiousness profile by allowing for transmission before symptom onset. We estimated
211 that 2.7% (95% CI: 1.0%, 5.0%) of transmission occurred prior to 7 days before illness onset,
212 22.5% (95% CI: 16.0%, 30.0%) started to become infectious 4 days before illness onset, and
213 the infectiousness peaked at 2.1 days (95% CI: 1.5, 2.7) before onset and then dropped
214 gradually, with 73.9% (95% CI: 67.2%, 81.3%) of transmission occurred before illness onset
215 and 97.1% (95% CI: 94.4%, 99.0%) of transmission occurred within 4 days after illness onset
216 (Figure 1C).

217

218 The estimated forward serial intervals decreased from 6.1 days (95% CI: 5.2, 7.1) on 25 May
219 2021 to 4.0 days (95% CI: 3.1, 5.0) on 18 June 2021 in the Delta outbreak (Figure 2B). By
220 using the time varying forward serial intervals and case incidence data, we estimated that the
221 R_t dropped rapidly from 9.3 (95% CI: 7.7, 11.6) on 25 May 2021 to 0.48 (95% CI: 0.42, 0.57)
222 on 18 June 2021, and had been below 1 since 9 June 2021 (Figure 2C). During the same time
223 period, the estimated infectiousness peak shifted from 0.23 days (95% CI: 0.20, 0.26) after
224 illness onset to 2.14 days (95% CI: 1.52, 2.70) before illness onset based on the time varying
225 serial interval (Figure 2D). By using the daily estimates of forward serial interval and R_t
226 during the exponential growth phase before 27 May 2021, the initial forward serial interval
227 was estimated to be 5.8 days (95% CI: 5.2, 6.1) (Figure 2B), and the R_0 was 6.4 (95% CI: 3.7,
228 9.3) (Figure 2C).

229

230 In total, 1314 throat swabs collected between 4 days before and 34 days after illness onset
231 were tested for 159 Delta cases. High viral loads were maintained between 4 days before
232 onset and 7 days after onset, then decreased gradually to a low but detectable level until about
233 Day 20 (Figure 3A). To compare viral loads between Delta and wild-type, we identified 94

234 cases with the median age of 46 years (IQR: 33, 61) infected with the wild-type virus in
235 Guangzhou city, Guangdong province in China between 21 January 2020 and 14 February
236 2020. Among those, 47 (50.0%) were male, the number of asymptomatic, mild and normal
237 were 2 (2.1%), 30 (31.9%) and 61 (64.9%), respectively, and no severe or critical cases were
238 identified. None of these cases received COVID-19 vaccination. In total 406 throat swab
239 samples were collected and tested on the illness onset day and 31 days after onset for the 94
240 wild-type cases. After excluding severe and critical cases and vaccinated cases, we found
241 during the period with a high viral load (0 to 7 days after onset), the median C_t values were
242 23.0 (IQR: 19.3-28.6) for N gene of the Delta variant, significantly lower than the values of
243 the wild-type N gene (median: 36.5, IQR: 33.0-40.0) (Figures 3B). Results of the GAMs
244 revealed that the C_t values of Delta cases who had one dose or two doses of vaccination were
245 on average 0.97 (95% CI: 0.19, 1.76) higher than unvaccinated cases after adjusting for days
246 of illness onset, age and disease severity (Figures 3C).

247

248 To evaluate individual infection risk and the effectiveness of vaccination on transmission for
249 the Delta variant, we analyzed infections among 5153 individuals who were close contacts of
250 73 COVID-19 cases. The overall secondary attack rate was 1.4% (95% CI: 1.1%, 1.8%) in
251 the contacts. The stepwise regression model showed that a high infection risk was among
252 those in older age (OR: 1.02, 95% CI: 1.01, 1.03), exposed to an index case without
253 vaccination (OR: 2.84, 95% CI: 1.19, 8.45) or with 1 dose of vaccination (OR: 6.02, 95% CI:
254 2.45, 18.16), and being household and extended family contacts (OR: 40, 95% CI: 24, 66)
255 (Table 1).

256

257 **DISCUSSION**

258 Our study provided a comprehensive assessment of the epidemiological characteristics of the
259 Delta variant. Higher transmissibility was demonstrated for the Delta variant, as indicated by
260 a higher reproduction number, shorter latent and incubation periods, and shorter serial
261 intervals compared to the wild-type SARS-CoV-2 (5, 13, 16-18). We observed higher viral
262 loads in cases infected with the Delta variant which might contribute to more rapid and
263 intense transmission. In addition, we found the inactivated vaccines could effectively reduce
264 viral loads in cases infected with the Delta variant and further lead to lower transmissibility.

265

266 We estimated the time varying forward serial intervals which considered the temporal
267 dynamics of the disease transmission in an outbreak (13, 14). The R_0 estimated for the Delta
268 variant was 6.4 which was substantially higher than the R_0 of the wild-type virus at the start
269 of the pandemic (16, 19). Estimation of the reproduction number could be underestimated
270 due to unobserved infections and neglecting the changes in the forward serial interval
271 distribution during the period of epidemic (14). In the Delta outbreak in China, active and
272 aggressive case-finding strategies using multiple PCR tests were implemented, which was
273 able to identify most infected persons including asymptomatic cases. With the shorter latent
274 and incubation period, and higher secondary attack rate among household and extended
275 family contacts, we believe multiple and more stringent interventions are needed to control
276 epidemics of the Delta variant. During the Delta outbreak in China, the local government had
277 implemented individual-based interventions such as case isolation, contact tracing and
278 quarantine, as well as population-level physical distancing measures such as lockdowns and
279 confinement (10, 13). More importantly, various community-wide PCR testing and routine
280 testing programmes among quarantined close contacts were aligned with the measures of
281 contact tracing and lockdown, aiming to identify and isolate the cases as early as possible and

282 interrupt transmission chains. The rapid drop in R_t within a week (Figure 2C) indicated the
283 effectiveness of these interventions.

284

285 We estimated that the 73.9% of transmissions occurred pre-symptomatically for the Delta
286 variant, which was higher than other variants (7, 20, 21), suggesting a higher transmission
287 potential of Delta cases before detection which was further supported by the high viral loads
288 at least 4 days before illness onset shown in our study. The high risk of transmission
289 particularly before onset indicated the need to expand contact tracing to a wider group of
290 contacts and perhaps to a longer time scale in order to control the epidemic caused by the
291 Delta variant (7, 22). However, for areas with a high prevalence of COVID-19, complete
292 contact tracing and quarantine outside the home may be infeasible as the number of contacts
293 is always several folds the number of infections (10). Physical distancing such as self-
294 isolation and home quarantine is more suitable in these areas. However, society-wide
295 physical distancing measures might increase transmission risk at household settings (10, 20).
296 Our study showed that the secondary attack rate (22.0%) among household close contacts of
297 Delta cases was higher than the rate obtained in 2020 (12.4%) in the same location with wild-
298 type infections (23).

299

300 We found that the viral load was higher in cases of the Delta variant than cases of the wild-
301 type virus, indicating a potentially higher infection rate per contact for the Delta (24). In
302 addition, patients infected with the Delta variant maintained a high viral load from 4 days
303 before illness onset. Besides, compared to the wild type, patients infected with Delta had a
304 slower decline in viral load towards the detection threshold of the PCR test (Figure 3B),
305 likely leading to a longer infectious period (24). Escape of the Delta variant from immunity
306 induced by wild-type variants (25) suggests that the herd immunity threshold needed to

307 suppress transmission of the wild-type virus may not be sufficient to control spread of the
308 Delta variant (24). Higher burden of SARS-CoV-2 is expected in the future given the
309 increasing predominance of the Delta variant all over the world. Additional booster doses of
310 vaccination might be able to increase protection against the Delta variant.

311

312 The effectiveness of the current vaccines from Pfizer-BioNTech and Oxford-AstraZeneca
313 appeared to diminish against infections with the Delta variant (25, 26). However, the efficacy
314 of the vaccines against transmission, which is another important indicator of their impact (27),
315 has rarely been reported. In this study, we observed that the C_t values among Delta cases
316 with one or two doses of vaccination were on average 0.97 higher than the unvaccinated
317 cases, indicating approximately 3-fold decrease in the quantity of viral RNA copies (28). The
318 vaccinated Delta cases in our study with a decreased viral load might have a reduced
319 transmission potential given that viral RNA load of SARS-CoV-2 was independently
320 associated with the shedding of transmissible viruses (29). The effectiveness of inactivated
321 vaccines against transmission of the Delta variant demonstrated the importance of increasing
322 vaccination coverage in mitigating COVID-19 (30).

323

324 Our study had several limitations. Self-reported symptom onset might bias estimates of the
325 parameters, e.g., leading to an overestimation of the incubation period if patients tended to
326 remember the later days with symptoms. Second, the C_t values used in our study were
327 obtained from different diagnostic kits which shared the same detection threshold but perhaps
328 with different sensitivity and/or specificity. Finally, in estimation of the serial interval,
329 transmission pairs with asymptomatic cases would be excluded due to absence of symptom
330 onset dates, which however might have biased the estimates of the reproduction number by
331 neglecting the impact of asymptomatic transmission.

332

333 In conclusion, the Delta variant demonstrated a higher transmissibility compared to the wild

334 type of SARS-CoV-2. An extension of contact tracing period to perhaps four days prior to

335 symptom onset may be needed considering the high proportion of pre-symptomatic

336 transmission and the high viral load before onset in infections with the Delta variant.

337 Inactivated vaccines appeared to be effective in reducing transmission of Delta infections and

338 a high vaccination coverage should be pursued to reduce the burden of COVID-19 pandemic.

339

340

341

342 **ACKNOWLEDGMENTS**

343 The authors thank Julie Au for technical support.

344

345 **FUNDING**

346 This project was supported by the National Natural Science Foundation of China (No.
347 82041030); Key-Area Research and Development Program of Guangdong Province (No.
348 2019B111103001); Theme-based Research Scheme (Project No. T11-712/19-N) of the
349 Research Grants Council of the Hong Kong SAR Government; and a commissioned grant
350 from the Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR
351 Government.

352

353 **POTENTIAL CONFLICTS OF INTEREST**

354 BJC reports honoraria from AstraZeneca, GlaxoSmithKline, Moderna, Roche and Sanofi
355 Pasteur. The authors report no other potential conflicts of interest.

356

357 **References**

- 358 1. B.1.617.2 Lineage Report. Alaa Abdel Latif, Julia L. Mullen, Manar Alkuzweny,
359 Ginger Tsueng, Marco Cano, Emily Haag, Jerry Zhou, Mark Zeller, Emory Hufbauer, Nate
360 Matteson, Chunlei Wu, Kristian G. Andersen, Andrew I. Su, Karthik Gangavarapu, Laura D.
361 Hughes, and the Center for Viral Systems Biology. outbreak.info, (available at
362 <https://outbreak.info/situation-reports?pango=B.1.617.2>). Accessed 10 July 2021.
- 363 2. World Health Organization .Weekly epidemiological update on COVID-19 - 3
364 August 2021. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly
365 Operational Update, (available at <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---3-august-2021>). Accessed 5 August 2021.
- 367 3. Zhencui L, Kai N, Kuibiao L, Yao H, Yang S, Min K, et al. Genome Characterization
368 of the First Outbreak of COVID-19 Delta Variant B.1.617.2 — Guangzhou City, Guangdong
369 Province, China, May 2021. China CDC Weekly. 2021;3(27):587-9.
- 370 4. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. The Spike
371 Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial
372 Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv.
373 2021:2021.05.14.444076.
- 374 5. Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and Transmission in a
375 large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv.
376 2021:2021.07.07.21260122.
- 377 6. Li Z, Liu F, Cui J, Peng Z, Chang Z, Lai S, et al. Comprehensive large-scale nucleic
378 acid-testing strategies support China's sustained containment of COVID-19. Nat Med.
379 2021;27(5):740-2.
- 380 7. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
381 shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-5.

- 382 8. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic
383 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat*
384 *Microbiol.* 2020;5(11):1403-7.
- 385 9. National Health Commission of the People's Republic of China. Guidelines in
386 Diagnosis and Treatment of COVID-19 (eighth version). (available at
387 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2021)
388 [july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2021)). Accessed 10 July 2021.
- 389 10. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities,
390 kinetics, and controllability of SARS-CoV-2. *Science.* 2021;371(6526).
- 391 11. World Health Organization .The Sinopharm COVID-19 vaccine: What you need to
392 know. WHO Strategic Advisory Group of Experts, (available at [https://www.who.int/news-](https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know)
393 [room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know](https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know)).
394 Accessed 10 July 2021.
- 395 12. World Health Organization .The Sinovac COVID-19 vaccine: What you need to
396 know. WHO Strategic Advisory Group of Experts, (available at [https://www.who.int/news-](https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know)
397 [room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know](https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know)). Accessed
398 10 July 2021.
- 399 13. Ali ST, Wang L, Lau EHY, Xu XK, Du Z, Wu Y, et al. Serial interval of SARS-CoV-
400 2 was shortened over time by nonpharmaceutical interventions. *Science.*
401 2020;369(6507):1106-9.
- 402 14. Park SW, Sun K, Champredon D, Li M, Bolker BM, Earn DJD, et al. Forward-
403 looking serial intervals correctly link epidemic growth to reproduction numbers. *Proc Natl*
404 *Acad Sci U S A.* 2021;118(2).

- 405 15. Cori A, Ferguson NM, Fraser C, Cauchemez S. A new framework and software to
406 estimate time-varying reproduction numbers during epidemics. *Am J Epidemiol.*
407 2013;178(9):1505-12.
- 408 16. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics
409 in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.*
410 2020;382(13):1199-207.
- 411 17. Xin H, Wong JY, Murphy C, Yeung A, Ali ST, Wu P, et al. The incubation period
412 distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
413 *Clin Infect Dis.* 2021.
- 414 18. Ali ST, Yeung A, Shan S, Wang L, Gao H, Du Z, et al. Serial intervals and case
415 isolation delays for COVID-19: a systematic review and meta-analysis. *Clin Infect Dis.* 2021.
- 416 19. Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. Serial Interval of COVID-19
417 among Publicly Reported Confirmed Cases. *Emerg Infect Dis.* 2020;26(6):1341-3.
- 418 20. Wu P, Liu F, Chang Z, Lin Y, Ren M, Zheng C, et al. Assessing asymptomatic, pre-
419 symptomatic and symptomatic transmission risk of SARS-CoV-2. *Clin Infect Dis.* 2021.
- 420 21. Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, et al. Evidence for pre-symptomatic
421 transmission of coronavirus disease 2019 (COVID-19) in China. *Influenza Other Respir*
422 *Viruses.* 2021;15(1):19-26.
- 423 22. Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility
424 of controlling COVID-19 outbreaks by isolation of cases and contacts. *Lancet Glob Health.*
425 2020;8(4):e488-e96.
- 426 23. Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household
427 secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a
428 retrospective cohort study. *Lancet Infect Dis.* 2020;20(10):1141-50.

- 429 24. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.
430 Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*.
431 2021;372(6538).
- 432 25. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
433 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*. 2021.
- 434 26. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
435 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*
436 (London, England). 2021;397(10293):2461-2.
- 437 27. World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines.
438 World Health Organization, (available at [https://cdn.who.int/media/docs/default-source/blue-](https://cdn.who.int/media/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf?sfvrsn=1d5da7ca_5&download=true)
439 [print/who-target-product-profiles-for-covid-19-](https://cdn.who.int/media/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf?sfvrsn=1d5da7ca_5&download=true)
440 [vaccines.pdf?sfvrsn=1d5da7ca_5&download=true](https://cdn.who.int/media/docs/default-source/blue-print/who-target-product-profiles-for-covid-19-vaccines.pdf?sfvrsn=1d5da7ca_5&download=true)). Accessed 10 July 2021.
- 441 28. A guide for health protection teams. Understanding cycle threshold (Ct) in SARS-
442 CoV-2 RT-PCR: a guide for health protection teams. Public Health England, (available at
443 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/926410/Understanding_Cycle_Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf)
444 [/file/926410/Understanding_Cycle_Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/926410/Understanding_Cycle_Threshold_Ct_in_SARS-CoV-2_RT-PCR_.pdf)).
445 Accessed 10 July 2021.
- 446 29. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N,
447 et al. Duration and key determinants of infectious virus shedding in hospitalized patients with
448 coronavirus disease-2019 (COVID-19). *Nat Commun*. 2021;12(1):267.
- 449 30. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What
450 defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical
451 efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis*. 2021;21(2):e26-e35.
452

Table 1. Secondary attack rate for close contacts of the Delta infectors, and the risk factors associated with the occurrence of infection based on backward logistic regression.

Characteristics	No. of close contacts	No. of infections (%)	Adjusted OR (95% CI)
Overall	5153	73 (1.4)	
Sex			
Male	2553	29 (1.1)	
Female	2600	44 (1.7)	
Age, years, median (IQR ^a)	47.0 (31, 66.5)		1.02 (1.01-1.03)
0-	424	12 (2.8)	
15-	2683	18 (0.7)	
45-	1521	27 (1.8)	
65-	525	16 (3.0)	
Type of index cases			
Asymptomatic and mild	1809	12 (0.7)	
Normal, Severe or critical	3344	61 (1.8)	
COVID-19 Vaccine dose of index cases			
0	2892	37 (1.3)	2.84 (1.19-8.45)
1 ^b	1110	31 (2.8)	6.02 (2.45-18.16)
2 ^c	1151	5 (0.4)	Referent
COVID-19 Vaccine dose of contacts			
0	2844	48 (1.7)	
1 ^b	1459	17 (1.2)	
2 ^c	850	8 (0.9)	
Type of contact			
Household and extended family	173	38 (22.0)	40 (24-66)
Others	4980	35 (0.7)	Referent
Exposure to an index case at onset ^d			
Yes	2106	49 (2.3)	
No	3047	24 (0.8)	
Duration of exposure, days, mean (sd)	7.8 (3.8)		
1-	1092	7 (0.6)	
6-	4061	66 (1.6)	

^a IQR: interquartile range

^b first COVID-19 vaccine dose 10 days before the first day of possible exposure to an infector

^c second COVID-19 vaccine dose was given 14 days before the first day of possible exposure to an infector

^d close contacts were exposed to an index at the time of the onset day of the index

FIGURE LEGENDS

Figure 1. The key epidemiologic time-delay distributions of Delta variant (red lines). (A)

The latent period distribution. (B) The incubation period distribution. (C) The infectiousness distribution. Vertical dotted lines show the mean estimates for latent period distribution and incubation period distribution, and the peak estimate for infectiousness profile. The triangles in A and B indicate the 95th percentiles for respective parameters.

Figure 2. The daily estimates of forward serial interval, instantaneous reproduction

number (R_t) and infectiousness peak. (A) The epidemic curve based on symptom onset dates of all cases in the Delta outbreak in Guangdong province. (B) The forward estimates of the serial interval over time. The dots represent the daily mean estimates of serial interval, and the vertical line segments represent the 95% CIs. The dashed line represents the initial (from transmission pairs with illness onsets of infectors before May 27, 2021) forward serial interval (5.8 days) (C) Mean estimates of R_t (line) and the 95% CIs (shaded area) based on the daily forward estimates of serial interval. The dashed line represents the basic reproduction number R_0 (6.4). The dotted line indicates $R_t=1$. (D) Estimates of the daily infectiousness peak after illness onset, based on daily estimates of the serial interval. The dots represent the daily mean estimates of infectiousness peak, and the vertical line segments represent the 95% CIs.

Figure 3. Temporal patterns of viral shedding for the Delta variant and the wild-type

SARS-CoV-2 virus. (A) Boxplot of threshold cycle (C_t) for N gene for all cases infected with the Delta variant. Light red curve and light pink shaded area indicate the fitted C_t values and the 95% CIs estimated from the generalized additive models (GAMs). (B) Boxplot of C_t values for N gene of Delta (red) and wide-type (blue) against time of sample collection

relative to the date of illness onset. The data for the Delta variant excluded severe, critical and vaccinated cases. (C) Boxplot of the predicted Ct values from the multivariate GAMs for unvaccinated (red) and vaccinated (blue, with one or two doses) cases.





